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Objectives: The aim of this study was to examine the empirical and methodological cost-effectiveness evidence of surgical interventions for breast, colorectal, or prostate cancer.
Methods: A systematic search of seven databases including MEDLINE, EMBASE, and NHSEED, research registers, the NICE Web site and conference proceedings was conducted in
April 2012. Study quality was assessed in terms of meeting essential, preferred and UK NICE specific requirements for economic evaluations.
Results: The seventeen (breast = 3, colorectal = 7, prostate = 7) included studies covered a broad range of settings (nine European; eight non-European) and six were published
over 10 years ago. The populations, interventions and comparators were generally well defined. Very few studies were informed by literature reviews and few used synthesized
clinical evidence. Although the interventions had potential differential effects on recurrence and mortality rates, some studies used relatively short time horizons. Univariate sensitivity
analyses were reported in all studies but less than a third characterized all uncertainty with a probabilistic sensitivity analysis. Although a third of studies incorporated patients’
health-related quality of life data, only four studies used social tariff values.
Conclusions: There is a dearth of recent robust evidence describing the cost-effectiveness of surgical interventions in the management of breast, colorectal and prostate cancers.
Many of the recent publications did not satisfy essential methodological requirements such as using clinical evidence informed by a systematic review and synthesis. Given the ratio
of potential benefit and harms associated with cancer surgery and the volume of resources consumed by these, there is an urgent need to increase economic evaluations of these
technologies.
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Health technology assessments (HTA) provide a connection be-
tween the research and decision-makingworlds and over the last
20 years have become central to informing healthcare policy de-
The research described in this article was funded by the Department of Health in England under
the Policy Research Unit in Economic Evaluation of Health and Care Intervention (EEPRU) based
at the University of Sheffield and University of York. The sponsors had no involvement in the
analysis or interpretation of the data or findings presented here or the decision to submit the
article for publication. We are grateful to our clinical advisors who provided excellent input along
the different stages of the research.
cisionmaking inmany settingsworldwide (1). TheHTAprocess
involves a systematic evaluation of the direct (intended) and in-
direct (unintended) effects and impacts of healthcare technolo-
gies. Organizations such as the Pharmaceutical Benefits Advi-
sory Committee (PBAC) in Australia, the Heath Care Insurance
Board (CVZ) in the Netherlands, and the National Institute for
Health and Care Excellence (NICE) in the United Kingdom
now publish guidelines to ensure consistency and transparency
in the HTA decision-making and reimbursement process
(2–4).
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Once the therapeutic value of novel interventions is estab-
lished, evidence of value for money and efficiency is required
before allocation of scarce healthcare resources in many set-
tings. To ensure consistency and increase the quality of evidence
submitted, NICE provides detail of a “reference case” for eco-
nomic evidence used to support submissions (4). While some
of NICE’s requirements (such as discount rates and perspec-
tives on costs) differ from those stipulated for non-UK settings,
many are essential requirements for any economic evaluation
in healthcare. These are clearly defined, relevant comparators;
systematic literature reviews for health effects; synthesis of clin-
ical evidence where applicable; suitable time horizons; health
related quality of life (HRQoL) data reported by patients; and
exploration of uncertainty (5–7). An often recommended cri-
terion, which is not standard across the board, is that results
are reported in terms of incremental cost per quality-adjusted
life-year (QALY) whereby the HRQoL weights for the QALY
are valued by the general population (4;8).
The last decade has seen a rapid growth in the volume
of literature describing economic evaluations of interventions
in healthcare. In particular the number of articles describing
cost-effectiveness evaluations in cancer has increased substan-
tially as new pharmaceuticals are brought to market. Surgery,
radiotherapy, and chemotherapy are the main treatments for
cancer (9), and considerable proportions of healthcare budgets
are consumed by these interventions. In 2010–2011, cancer was
the third largest category of the overall UK healthcare budget,
accounting for 5.4 percent of the overall cost at £5.8 bn (EUR
7.24 bn) (10),while total economic costs attributed to colorectal,
breast, and prostate cancers were estimated to be £1.6 bn (EUR
2.0 bn), £1.5 bn (EUR 1.87 bn) and £0.6 bn (EUR 0.75 bn),
respectively (11). Although the clinical and cost-effectiveness
of novel pharmaceutical interventions for cancer is well doc-
umented due to the submission processes for reimbursement
in many settings, it is unclear whether existing and novel sur-
gical and radiotherapy interventions are treated with the same
rigorous scrutiny.
The objective of the study was to examine the method-
ological and empirical cost-effectiveness evidence specifically
in relation to surgical interventions in breast, colorectal and
prostate cancer. Relevant literature was identified through sys-
tematic searches and methodological standards were assessed
using quality criteria, both essential and preferred, and informed
by the NICE reference case.
METHODS
Search Strategy
Systematic searches were undertaken (April 2012) in the fol-
lowing databases: Medline, EMBASE, CDSR, NHSEED, HTA,
DARE, and EconLit. The CEA registry, the NICE website, re-
cent conference proceedings, and reference lists of any included
studies and existing reviews were also searched. No language,
publication, or date restrictions were applied to the searches.
The full search strategy is available online (12).
Study Selection Strategy
Studies were selected for inclusion in two stages. An initial
sieve was conducted on title and abstract and full articles were
retrieved for any potentially relevant studies. Studies were in-
cluded in the reviews if they assessed the cost-effectiveness of a
surgical technique in individuals with either breast, colorectal,
or prostate cancer, and presented results in the form of an incre-
mental cost perQALYor an incremental cost per life-year [LY]).
Data were extracted using a customized template designed to
capture relevant information (Table 1–2). Studies were qual-
ity appraised (Figure 2) in terms of meeting essential (items
1–7: patient group and indication clearly defined, comparators
clearly defined, effectiveness evidence based on a systematic re-
view, appropriate time horizon, HRQoL data reported directly
by patients or carers, probabilistic sensitivity analysis used to
quantify uncertainty), preferred (items 8–9: cost-effectiveness
analysis using QALYs, HRQoL preference data valuation by
representative sample of the public), and UK NICE specific
(items 10–14: 3.5 percent discount rate, comparators used in
NHS, UK setting, UK NHS and personal social services costs,
cost per QALY below the NICE threshold value, assumed to
be £30 k per QALY for evaluations in cancer (i.e., society is
willing to pay £30k [EUR 37.4 k] for one additional QALY)
requirements for economic evaluations in healthcare (4). Many
of the criteria that were applied are relevant to economic mod-
els irrespective of setting and the preferred items overlap with
those in published quality checklists (8;13). The evidence was
reviewed by a single researcher and any issues were discussed
within the review team until a consensus was achieved in cases
of uncertainty or lack of clarity.
RESULTS
The searches identified 1,133, 2,408, and 722 unique references
for the breast, colorectal and prostate cancer reviews, respec-
tively (Figure 1). Seventy-eight full papers were retrieved for
detailed inspection. Of these, sixteen studies met the inclusion
criteria (Table 1). One additional study published after comple-
tion of the searches was identified and has been included in this
article.
Three studies were in breast cancer (publication dates 1997
to 2003) (14–16), seven were in colorectal cancer (publication
dates 2000 to 2011) (17–23) and seven were in prostate cancer
(publication dates 2000 to 2012) (24–30). Two of the three
breast cancer studies were set in the United States (14;16), and
one was in Norway (15). Two of the seven colorectal studies
were set in the United Kingdom (18;23), two in the United
States (21;22), one in Canada (19), one in New Zealand (20),
and one in Spain (17). Three of the seven prostate studies were
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Table 1. Characteristics of the Studies Included
Author, year Setting Population Stage Intervention Comparator Time horizon Clinical evidence
Breast cancer
Norum, 1997(15) Norway Women diagnosed with early stage
breast cancer
Stage I and II BCS – lumpectomy MRM 10 years Several clinical
studies
Malin, 2002(14) US 8 hypothetical women classified based on
their estrogen-receptor type (positive
or negative), lymph node type
(positive or negative), and age (45 or
60 years of age)
Stage I,II and III a) Adjuvant therapy
strategies after surgery,
b) radiation after BCS, c)
reconstruction after
surgery
Mastectomy alone Lifetime Several RCTs
Polsky, 2003(16) US Women 65 years of age or older, who
were diagnosed early stage breast
cancer between 1992 and 1994
Stage I and II BCSRT Mastectomy 5 years National survey
cohort
Colorectal cancer
Miller, 2000(22) US Locally recurrent rectal cancer patients
(n = 68), 62% were males, median
age was 58, median time from
diagnosis to surgery was 24 months
and median time from diagnosis to
reoccurrence was 14 months
Locally recurrent rectal
cancer
Surgical resection Diagnostic or
palliative
surgery
3.5 years Patients’ records
for survival and
resource use
Govindarajan,
2006(19)
Canada 70-year-old male with a complete
emergent malignant left colonic
obstruction secondary to a left-sided
colon cancer with no evidence of
metastatic disease.
Stages II, III and IV Emergency colonic stenting
as a bridge to definitive
surgery
Emergency surgery Lifetime Meta-analysis
Murray, 2006(23) UK A cohort of 65-year-old colorectal cancer
patients
Stages I, II and III LS OS 25 years Mixture of RCTs, a
meta-analysis,
and
assumptions
deVerteuil,
2007(18)
UK Colorectal cancer patients over 50 years
of age
Different stages have
been considered as
subgroup analysis
(results are not
reported)
LS OS 25 years Meta-analysis
Hayes, 2007(20) New Zealand Colorectal cancer patients from
meta-analysis of several trials
No reference to stage Laparoscopic-assisted
colectomy (LAC)
Conventional open
colectomy (OC)
Not stated Two clinical studies
Callejo, 2011(17) Spain Colorectal cancer No reference to stage LS OS No information Meta-analysis
Jensen, 2011 (21) US Colon or rectal cancer No reference to stage LS OS No information No information
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Table 1. Continued.
Author, year Setting Population Stage Intervention Comparator Time horizon Clinical evidence
Prostate cancer
Jager, 2000(26) US A cohort of 65 year-old men with
prostate cancer eligible for RP
No reference to stage RP based on MR imaging
(extra capsular disease
contraindicates RP)
RP based on
clinical staging
Lifetime Clinical studies
Calvert, 2003(24) UK 60-year-old men diagnosed with
moderately differentiated (Gleason
sum score 5 – 7) prostate cancer
Early stage localised
prostate cancers
DNA-ploid test followed by
RP for those with
nondiploid test
a) RP for all,
b) WW and
monitoring
Lifetime Limited detail
O’Malley, 2007(29) Australia Prostate cancer patients eligible for
surgery
Late stages as the
patients are
undergoing surgery
LRARP Open RP 1 year Cohort
NICE, 2008(ref) UK Men with clinically localised PC Stages I to IV RP WW 20 years Clinical trial
Hohwu, 2011(25) Denmark Retrospective cohort study a total of 231
men (50 to 69 years of age) and with
clinically localised prostate cancer
underwent RP
PC stages cT1-T2 RALP RRP 1 year Retrospective
cohort
Lyth, 2012(27) Sweden 695 patients enrolled in SPCG-4 trial
between October 1989 and February
1999. Eligible patients were aged less
than 75 years, life expectancy was
greater than 10 years and no other
malignancy was present. The
prostate-specific antigenvalue had to
be below 50 ng/ml.
Patients with newly
diagnosed tumours
that are localized to
the prostate
RP WW Lieftime RCT
Ramsey 2012(30) UK Men with localised prostate cancer
undergoing radical prostatectomy at
designated pelvic cancer surgical
treatment centres within the UK NHS
Stage I to IV Laparoscopic prostatectomy
and robotic prostatectomy
OS 10 years Systematic review
BCS, breast conserving surgery; BSCRT, breast conserving surgery with radiation; CEA, cost-effectiveness analysis; LRARP, laparoscopic remotely assisted radical prostatectomy; LS, laparoscopic surgery; LY, life-year;
MRM, modified radical mastectomy; MR, magnetic resonance; OS, open surgery; QALY, quality adjusted life year; RP, radical prostatectomy; RALP, Robot-assisted laparoscopic prostatectomy; RRP, retropubic radical
prostatectomy; WW, watchful waiting.
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Table 2. Methods and Study Conclusions
Author, year Synopsis of methods Study conclusion
Breast cancer
Norum, 1997(15) CEA with a focus on the cost of surgery, radiotherapy, adjuvant therapy, follow up, and the
cost of relapse
BCS is cost-effective and should not be displaced by mastectomy. BCS following MRM may
be considered but there was little evidence to support this treatment option.
Malin, 2002(14) CEA that combines short-term gains from surviving the first 10 years with gains from
reduced rates of breast cancer recurrence over the rest of the woman’s life
Adjuvant therapy after surgery, BCS with radiation and reconstruction after mastectomy
tend to be more cost-effective than surgery alone.
Polsky, 2003(16) Retrospective cohort study with two CEAs – a traditional analysis that compared
mastectomy as the standard of care with BCSRT as the new intervention and an
alternative CEA where the standard of care is assumed to be an open regimen in which
both BCSRT and mastectomy are widely available
Providing a choice between mastectomy and breast conservation surgery is economically
attractive when the economic analysis includes the benefit of patient choice of treatment.
Colorectal cancer
Miller, 2000(22) Economic evaluation using institution records Patients with recurrent rectal carcinoma assess the discomfort due to surgery and morbidity
to be less severe than health care providers. Surgical resection may be a cost-effective
intervention, particularly when cost-effectiveness is calculated using patient preferences.
Govindarajan, 2006(19) Markov Model Colonic stenting as a bridge to surgery is more effective and less costly than surgery in the
treatment of emergent, malignant left colonic obstruction.
Murray, 2006(23) Markov model that allows a cohort of patients to progress from their initial operation to
convalescence to “disease free” state or death
Laparoscopic resection is associated with a quicker recovery period with no evidence of a
change in the mortality rate for a modest additional cost (between £250 and £300 per
patient), although operation times were longer. Assuming equivalence of long- term
outcomes, a judgement is required as to whether the benefits associated with earlier
recovery are worth this extra cost.
deVerteuil, 2007(18) Markov model for a cohort of patients from their initial operation to convalescence to
“disease free” state or death
LS is likely to be associated with short-term quality of life benefits, similar long-term
outcomes, and an additional £300 per patient. A judgment is required as to whether the
short-term benefits are worth this extra cost.
Hayes, 2007(20) Costing exercise with hospital cost data & RCT recovery data LAC for cancer appears to be cost-effective relative to OC for the lower of the average cost
estimates but there is a great deal of uncertainty around the costs. Potential future
reductions in operating times, conversion rates and postoperative stays are likely to
further improve cost-effectiveness.
Callejo, 2011(17) Markov model Although the cost for LS was higher than for OS, LS appeared to accelerate recovery time
Jensen, 2011 (21) Model based Laparoscopic resection for colon and rectal cancer results in both decreased costs and slight
improvements in quality of life, making it the preferred approach in suitable patients
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Table 2. Continued.
Author, year Synopsis of methods Study conclusion
Prostate cancer
Jager, 2000(26) Decision tree model with two assumptions: i) MR staging was performed in addition to
other staging methods in patients considered candidates for radical prostatectomy and ii)
extra-capsular disease on MR images contraindicates surgery.
It is not yet conclusively determined whether preoperative MR staging is appropriate, but
results of decision analysis suggest that MR staging is cost-effective for men with
moderate or high prior probability of extracapsular disease.
Calvert, 2003(24) Markov model A treatment selection policy based on DNA-ploidyanalysis would be cost-effective if the test
can achieve specificity levels at or above 80%.
O’Malley, 2007(29) Economic evaluation with data from a cohort study The incremental cost-effectiveness for LRARP compared with open surgery is well below the
accepted Australian pharmaceutical threshold.
NICE, 2008(ref) Markov Model which took into account the progression of the patients underlying prostate
cancer and the side effects due to individual treatments.
The cost-effectiveness of radical prostatectomy is dependent on the health outcomes
included. If only patient survival is considered, then radical prostatectomy is arguably
cost-effective. When quality-of-life considerations for prostate cancer and
treatment-related side effects are included, watchful waiting becomes the dominant
option.
Hohwu, 2011(25) Economic evaluation alongside a retrospective cohort study RALP was more effective and more costly. A way to improve the cost effectiveness may be
to perform RALP at fewer high volume urology centres and utilise the full potential of
each robot.
Lyth, 2012(27) A semi-Markov model that use symptomatic disease instead of hormonally controlled
metastasis and use refractory disease instead of refractory metastasis, with an
assumption that the patients cannot die of PC unless they have developed a refractory
disease.
The cost-effectiveness ratio for RP varies with age, Gleason score and prostate-specific
antigen values. RP was not perceived to be cost-effective in men aged 75 years with low
Gleason and low PSA. Higher threshold values for patients with clinically localized
prostate cancer could be discussed.
Ramsey 2012(30) An individual-based event model constructed by discrete-event simulation approach Robotic prostatectomy had lower perioperative morbidity and a reduced risk of a positive
surgical margin compared with laparoscopic prostatectomy, although there was
considerable uncertainty.
BCS, breast conserving surgery; BSCRT, breast conserving surgery with radiation; CEA, cost-effectiveness analysis; LRARP, laparoscopic remotely assisted radical prostatectomy; LS, laparoscopic surgery; LY, life year;
MRM, modified radical mastectomy; MR, magnetic resonance; OS, open surgery; QALY, quality-adjusted life-year; RP, radical prostatectomy; RALP, Robot-assisted laparoscopic prostatectomy; RRP, retropubic radical
prostatectomy; WW, watchful waiting.
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Economic evidence of surgical procedures in cancer
Citaons idenﬁed by searches 
 
Breast Cancer: N=1154 
Colorectal Cancer: N=3226 
Prostate Cancer: N=1078 
 
 srepap etacilpud – dedulcxE  
 
Breast Cancer: N=21 
Colorectal Cancer: N=818 
Prostate Cancer: N=356 
 
Papers screened by tle/abstract 
 
Breast Cancer: N=1133 
Colorectal Cancer: N=2408 
Prostate Cancer: N=722 
 
  
 noisulcni eht teem ton did srepap – dedulcxE  
criteria 
 
Breast Cancer: N=1109 
Colorectal Cancer: N=2375 
Prostate Cancer: N=701 
 
Full papers retrieved for detailed inspecon 
 
Breast Cancer: N=24 
Colorectal Cancer: N=33 
Prostate Cancer: N=21 
 
  
 noisulcni eht teem ton did srepap – dedulcxE  
criteriaa  
 
Breast Cancer: N=21 
Colorectal Cancer: N=24 
Prostate Cancer: N=15 
 
Potenal studies to be included in the review 
 
Breast Cancer: N=3 
Colorectal Cancer: N=7 
Prostate Cancer: N=(6+1b)=7 
 
  
 
a details of exclusions are provided in the full report(12) 
b One addional study was included which was published aer the searches were conducted 
Figure 1. Flow diagram for study inclusion.
set in the United Kingdom (24;28;30), with the remaining four
in Australia (29), Denmark (25), Sweden (27), or the United
States (26). The studies scan a broad publication range with six
published before 2004 (older publications) and five published
after 2010 (recent publications). Of particular interest, there
were no publications for breast cancer after 2003.
Essential Basic Requirements
Defined Research Question. A basic requirement of any economic eval-
uation in health care is a clear andwell defined decision problem
which states both the exact clinical definition of the indication
of interest, and detailed information on the interventions being
compared (4). This enables reviewers and readers to assess if
the analyses and results are relevant to their own settings and
practice. The patient populations were reasonably well defined
in the majority of studies (Figure 2), but there were exceptions.
In the colorectal and prostate studies, the exact patient popula-
tion or stage of cancer was either not clear or was not provided
in some articles (17;20;21;26).
The interventions and comparators were generally clearly
defined in all the studies. The three breast cancer studies com-
pared breast conserving surgery with mastectomy with one
also comparing reconstruction after surgery (14). Six of the
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Essenal requirements                  
Paent group/indicaon clearly deﬁned + + + + + + +/- +/- +/- + + + +/- + + + + 
Comparators clearly deﬁned + + + + + + + + + + + + + + + + + 
Eﬀecveness evidence based on a systemac review - - - - + + + + + - - - - - - - + 
Appropriate me horizon - + + - + + + - - - + + + + + + - 
HRQoL data reported directly by paents &/or carers - - + + + - + + - - - - - ? + + + 
Probabilisc sensivity analysis used to quanfy uncertainty - - - - + + - - + - - - - - - + + 
Relevant one-way sensivity analyses - + + - + + + + - + + + - + + + + 
Preferred requirements                  
Cost-eﬀecveness analysis using QALYs + + + + + + + + + + + + + + + + + 
HRQoL preference data valuaon by representave sample of the public - - - - - - + + - - ? + - - + - ? 
UK/NICE speciﬁc requirements                  
Discount rate, 3.5% - - - - - - - - - - - - - + - + + 
Comparators used in the NHS + + + + + + + + + + + + - + + + + 
UK Seng - - - + - + + - - - - + - + - - + 
UK NHS and personal social services costs + + + - - + + - - - - + - + - - + 
Cost/QALY < NICE threshold value +** +** - - +** - - - +a +b +** +** +** +/- - +/- +** 
**Cost/QALY < GBP 20k (EUR  25k) NICE threshold value, *Cost/QALY < GBP 30k (EUR 37.4k) NICE threshold value. aCost-eﬀecve under EUR 36.7k. bprobability of cost-eﬀecveness 60% considering a willingness-to-
pay between EUR 25k/QALY and EUR 37.4k/QALY 
E=essenal basic requirements of any economic evaluaon, P=preferred requirement, UK=requirement speciﬁc to UK NICE reference case 
 
+ Sasﬁes requirements - Does not sasfy requirements +/- Parally sasﬁes requirements ? Unclear or informaon not provided
 
Figure 2. Quality of included studies compared to the NICE reference case.
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Economic evidence of surgical procedures in cancer
colorectal studies compared laparoscopic surgery with open re-
section (17;18,20;21;23), one compared surgical resection with
diagnostic or palliative surgery (22), and one compared emer-
gency colonic stenting as a bridge to definitive surgery with
emergency surgery (19). Two of the prostate cancer studies com-
pared radical prostatectomy with watchful waiting (27;28), one
compared radical prostatectomy for those with non-diploid test
with either radical prostatectomy for all or, watchful waiting
(24), one compared radical prostatectomy based on magnetic
resonance (MR) imaging with radical prostatectomy based on
clinical staging (26), one compared laparoscopic remotely as-
sisted radical prostatectomy with open radical prostatectomy
(29), one compared laparoscopic prostatectomy and robotic
prostatectomy with open surgery (30), and the final study com-
pared robot-assisted laparoscopic prostatectomy with retropu-
bic radical prostatectomy (25).
Clinical Evidence. Another essential requirement relates to the clini-
cal data used to quantify potential benefits of the interventions
under evaluation. Evidence of a full literature search and, where
appropriate, a synthesis of evidence on health effects informed
by the systematic review, are mandatory to ensure the data used
represent all the evidence available at the time of the study and
the associated uncertainty surrounding the point estimates (2–
4;6). The effectiveness rates used in the majority of the studies
included in this study were not informed by systematic litera-
ture reviews or a synthesis of all available data. In breast cancer,
none of the studies used effectiveness evidence informed by a
systematic literature review or a synthesis of data. In colorec-
tal cancer, five of the seven studies used the results of meta-
analyses (17–20;23). One study used event rates observed in
a single hospital as per their research question (22), and one
provided insufficient detail to determine the source of the effec-
tiveness evidence used (21). In prostate cancer, one study used
the results of a meta-analysis (30), two used data from single
randomized control trials (RCTs) with no evidence to suggest
alternative evidence was used in sensitivity analyses (27;28),
two used data from retrospective cohort studies (25;29), one
study was informed by a mixture of evidence from RCTs and
observational data obtained from a systematic search supple-
mented by expert opinions (26), and one provided insufficient
detail to determine the source (24).
Time Horizon. Many of the interventions will have a differential
effect on recurrence rates and/or mortality risk hence the most
appropriate time horizon for the costs and benefits would be
a lifetime (4). However, for individuals with cancer, a lifetime
horizon is potentially considerably shorter than that of the gen-
eral population due to the reduced life expectancy associated
with the condition. Over half (10/17) of the studies took account
of longer-term costs and benefits associated with the interven-
tions using aminimumof 10 year horizons (14;18–19;23;24;26–
28). The remaining studies arguably underestimated both the
costs and benefits of the interventions. One study used the aver-
ageweighted survival duration (42months for resected patients)
(22). One restricted costs and QALYs to the first post-operative
year (25), while one used 5-year retrospective data without ex-
trapolating either costs or benefits (16). Two studies, which
limited the perspectives to that of single hospitals, presented
incremental benefits over short horizons without extrapolating
to account for downstream benefits or costs. One restricted the
time horizon to length of stay, estimating the incremental dif-
ference in recovery time (20), while the second study estimated
the reduction in months (range, 3.79 to 8.67 months) of incon-
tinence or erectile dysfunction (29).
HRQoL. HRQoL data should be collected directly from patients
with the conditions described in the economicmodel and prefer-
ably from patients in receipt of the interventions under evalua-
tion (4;7).When it is not possible for patientswith the conditions
to provide these values, then proxy values may be obtained from
their principle carer. However, values obtained from healthcare
professionals are not appropriate and have been shown to differ
substantially from those obtained from patients with the condi-
tion being valued (31).
The description of sources of HRQoL data was poor in
many of the studies. While over a third of the studies (7/17)
incorporated HRQoL data which were collected directly from
individuals with the condition of interest, three studies used
HRQoL data obtained from clinicians (14;15,22;23), or nurses
(15;23), and one study assumed HRQoL values based on the
New Zealand social tariff (20). There was insufficient evidence
to determine the source of the HRQoL data in six of the studies
(15;17;21;24;26;29).
Uncertainty. All economic evaluations should accurately charac-
terize the decision uncertainty associated with the interventions
under evaluation. At the very least, univariate sensitivity anal-
yses should be conducted to illustrate both structural uncer-
tainty (for example assumptions relating to the description of
the clinical pathway, or the extrapolation of data) and uncer-
tainty around key parameter values (for example if different
sources for HRQoL or cost data are available) (4). Ideally, a full
probabilistic sensitivity analysis usingMonte Carlo simulations
would be performed to demonstrate the uncertainty around the
mean point estimates used (8), and is encouraged by several
decision-making bodies (3;4;6).
The majority of studies (13/17) performed univariate sensi-
tivity analyses to illustrate the effect on results associated with
variations in key parameter inputs.Many of the authors reported
cost-effectiveness results were sensitive to changes in param-
eter values and particularly for recurrence rates, hernia rates,
HRQoL values, and side-effects of treatments. The full range of
uncertainty was poorly captured with less than one third (5/17)
of the studies presenting the results of a full probabilistic sen-
sitivity analysis (17;19;23;27;30). It is perhaps surprising that
some of the newer publications did not report these results as this
is now considered to be standard practice in health economics.
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Preferred Requirements
Although the preferred outcome from economic evaluations
varies depending on the reimbursement body, the cost per
QALY, where the valuation of the HRQoL is based on pub-
lic preferences, is now a pivotal requirement for submissions
to NICE (4). The QALY describes both survival and HRQoL
weights in a single metric and is the recommended gold stan-
dard to facilitate comparison across disparate conditions and
equity in policy decisions (8). Although all studies reported
results in terms of a cost per QALY (or cost per quality ad-
justed month) (19), few (4/17) used general population weights
for all utilities (18;20;24;25). One study mapped from HRQoL
values onto a scale assuming 0 and 100 were equal to death
and full health, respectively (15), while two studies used patient
values from the patients’ completed Euroqol VAS, again assum-
ing 0 and 100 were equal to death and full health, respectively
(16;27). Three studies elicited weights from clinicians using
standard gamble (14;22;23), while a fourth used time-trade off
to derive values from patients. Six studies provided insufficient
detail to determine if general population weights were used
(14;15;17;21;26;29).
UK Specific Requirements
Discount rates are both jurisdiction and time dependent and
are used to ensure results reflect the present value of the cost
and benefits accrued over the duration of the analyses (4). Not
surprisingly, due to the differences in settings and the pub-
lication dates, only 3/17 of the studies used the current UK
recommended discount rates (3.5 percent per annum) for costs
and benefits (27;28;30). However, all studies that used horizons
over one year did discount costs and effects.
While some reimbursement bodies restrict the perspective
to the direct healthcare resource costs and savings directly at-
tributed to a health service, others take a broader societal view
and require indirect costs such as productivity losses or care-
giver’s time (5). Two-thirds (13/17) of the studies limited costs
to direct healthcare costs (14–16;18–20;22–24;26–30), and two
of these restricted costs to those directly incurred by hospitals
(20–22). The remainder took a broader perspective and costs
such as productivity losses (21;25), and caregiver’s time (21),
were included.
Applying the NICE threshold value of GBP 20–30 k
(EUR 25–37.4 k) per QALY, irrespective of the time of
publication, the setting or adherence to the NICE methods
guide, breast conserving surgery plus axillary mode dissection
compared with modified radical mastectomy would be con-
sidered cost-effective while breast conservation surgery with
radiation therapy compared with mastectomy would not be
considered cost-effective (14). There are multiple reasons for
this including cosmesis, patient preferences, and the added
cost of reconstruction which is used after mastectomy in
over 20 percent of all cases and recurrence rates requiring
further interventions (32;33). It should be noted that the latter
comparator is no longer appropriate in the current clinical
context as it is now current practice, with rare exceptions, for
radiation to be administered after conservation therapy.
Applying the GBP 20–30 k (EUR 25–37.4 k) per QALY
threshold to the studies on colorectal cancer, the probability
that laparoscopic surgery would be considered cost-effective
compared with open surgery ranged between 30 percent (18)
and 40 percent (23) and univariate analyses produced results
where laparoscopic surgery either dominated (higher costs and
lower benefits) open surgery or was dominated (lower costs and
larger benefits) by open surgery suggesting considerable uncer-
tainty (18;20;23). The evaluation of emergency colonic stenting
as a bridge to definitive surgery dominated emergency surgery
in individuals with emergent, malignant left colonic obstruc-
tion (19), and non-surgical treatment dominated both surgical
resection and diagnostic/palliative surgery in individuals with
recurrent colorectal cancer (22).
Applying the GBP 20–30 k (EUR 25–37.4 k) per QALY
threshold to the studies for prostate cancer, radical prostate-
ctomy treatment is unlikely to be considered cost-effective
comparedwithwatchful waiting due to considerable uncertainty
around the incremental cost-effectiveness ratio (ICER). Again,
the cost per QALY results ranged from below GBP 20 k (EUR
25 k) per QALY (except for men aged 75 and over) when the
decision was based on patient survival only (27), to dominated
when side effects of the surgical technique were taken into
account (28). While a marker-based (DNA-ploidy) treatment
selection policy would be considered cost-effective compared
with watchful waiting using these thresholds, both policies
dominated the “prostatectomy for all” option (24). However,
the ICER was highly sensitive to factors such as sensitivity and
specificity (24), and in one study the ICER ranged from approx-
imately GBP 2 k (EUR 2.5 k) per QALY to GBP 84 k (EUR 105
k) per QALY (27). Robotic prostatectomy was likely to be cost-
effective at GBP 30 k (EUR 37.4 k) per QALY in comparison
to laparoscopic prostatectomy when the number of procedures
performed per year with the robotic system was over 150 (30),
whereas radical prostatectomy was cost-effective at GBP 20 k
(EUR 25 k) per QALY threshold compared with open surgery
(29).
DISCUSSION
The limited numbers of studies included in the reviews highlight
the scarcity of economic evidence for surgical procedures in
these indications. The searches identified just three studies for
breast cancer surgery, all were published before 2003 (14–16).
Of the seven colorectal cancer studies, only two were published
after 2010;(17,21) and of the seven prostate cancer studies, three
were published after 2010 (25;27;30).
Although some UK specific requirements were included
in the methodological checklist (Figure 1), the vast majority of
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criteria used to assess the scientific rigor of the studies are funda-
mental requirements for any economic evaluation in health care
and are, therefore, generalizable to other settings and decision-
making bodies. Scientific rigor is improving in economic eval-
uations generally, and older publications may not conform to
current practice. The studies included in the reviews cover a
broad publication range with six (6/17) published before 2004
(older publications) and five (5/17) published after 2010 (recent
publications). Assessing the studies chronologically (Figure 2),
there is a marked difference in the proportion that satisfies the
essential criteria. For example, although only 5/17 of all the
studies reported results of full probabilistic sensitivity analyses,
none (0/6) were older publications and three (3/5) were recent
publications. Similarly, although only 6/17 used a systematic
review and meta-analysis to inform the clinical evidence used,
none (0/6) were older publications and three (3/5) were recent
publications. Similar rates were observed for the use of HRQoL
data reported directly by the patients or carers with none (0/6)
of the older publications using these data compared with two
(2/5) of the recent publications. While the majority of the older
evaluations were not undertaken using the current requirements
for sources of evidence (clinical data informed by a systematic
literature review/synthesis, HRQoL data from patients with the
condition) and uncertainty (probabilistic sensitivity analysis)
the recent publications would be expected to conform to these
basic standards.
There were several essential requirements which were not
satisfied in many of the publications. First, much of the clini-
cal evidence was not supported by a systematic review of the
literature or a synthesis of the relevant evidence, and very few
authors presented the results of a full probabilistic sensitivity
analysis. Relying on the effectiveness evidence from a single
clinical study or hospital setting in isolation, with no reference
to the relevant published evidence, can be misleading as the
effectiveness evidence from a single study may differ substan-
tially from other evidence in the area. This may hinder and
even mislead policy decision makers in some cases. While it is
not always possible to conduct a full systematic literature re-
view and evidence synthesis within the resource allocations of
a project, it is generally possible to compare the effectiveness
evidence used with the literature. If the data used are compa-
rable to the published literature, this will increase confidence
in the results presented. If the data differ substantially from the
published literature, then the results obtained using the differ-
ent values should be compared (preferably using a probabilistic
sensitivity analysis) to determine if the evaluation is sensitive
to variations in these parameters. Exploring the uncertainty
around the point estimates is particularly relevant if the evi-
dence comes from a novel interventionwhere there is no existing
evidence.
The second and closely related area where many of the
studies failed to meet requirements was in the choice of time
horizon used to sum the benefits and costs accrued from the
alternative interventions. It is widely accepted that if an inter-
vention has a differential effect on survival, themost appropriate
horizon would be a lifetime. As the patients in the evaluations
had cancer, then a shorter horizon (say 10 to 20 years) may be
considered sufficient. However, many of the studies restricted
the horizon to less than 5 years, or did not provide details of the
length of horizon used. It is unlikely that a time horizon of 1 year
will accurately reflect the full benefits of an intervention in pa-
tients with cancer. While some analysts may be reluctant to rely
on assumptions to extrapolate beyond the duration of the clin-
ical evidence, the effect of longer horizons should be explored
in sensitivity analyses to determine what if any difference this
makes to the results generated.
The final area where many of the studies failed to satisfy the
essential requirements relates to the HRQoL data used within
the analyses. Over half of the studies did not use data col-
lected from patients (or their carers) with the particular condi-
tions. Reporting standards for both the source of evidence and
the methodology used to collect these data were particularly
low. Many policy makers require that the preference-weights
used to determine QALYs are obtained from the general pop-
ulation. There is an argument that in some health conditions,
generic measures such as the EQ-5D may not be sensitive to
small changes in dimensions of health or features of a partic-
ular condition. In these cases, a condition specific measure of
health, such as the Functional Assessment of Cancer Therapy
(FACT) for patients with cancer, may be more relevant (34). At
the moment the FACT measure does not have a corresponding
preference-weighted index which could be used to determine
the QALYs in an economic evaluation. While several of the
studies (4/17) conducted analyses to elicit preference weights
for defined health states in the evaluations, in many of the stud-
ies it was impossible to determine what preference-weights, if
any, had been used.
To our knowledge, little or no research has been conducted
to date which has compared the equivalence of reporting stan-
dards for economic evaluation for surgical procedures and those
for pharmaceutical products. Comparing methods and stan-
dards in economic evaluation of medical devices and drugs,
authors highlighted key challenges for evaluating medical de-
vices. These may generalize to surgical interventions including
the practical difficulties in conducting randomized controlled
trials (35–36), the dependence of outcome on the surgeon’s
expertise (35). and the wider organizational impacts associ-
ated with introducing new devices which may differ by location
(35–36). In some countries (for example Australia and Canada),
HTAs and cost-effectiveness analyses focus on pharmaceuticals
rather than the full range of health-care technologies, whichmay
go some way to explaining why there is a dearth of evidence on
surgical interventions.
Given the scarcity of literature and relatively dated clin-
ical evidence for some of the indications and procedures, it
is reasonable to question what economic evidence is used to
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support clinical guidelines in these areas. In the United King-
dom, the number of HTA and NICE guidance issued can be
used as an indicator of the priority given to cancer health
care (37;38). Since its inception, NICE has issued guidance
relating to twenty-eight (11;13) pharmaceutical interventions
and seven (13) intervention procedures for breast (colorectal,
prostate) cancer, and there have been forty-five (25;32) HTA
submissions.
The most recent clinical guideline for early (and locally
advanced) breast cancer has very limited de-novo evidence
in terms of alternative surgical techniques (39;40), The cost-
effectiveness literature was not reviewed under the following
topics: “Surgery to the breast” (includingPaget’s disease), “eval-
uation and management of a positive lymph node” and “breast
reconstruction” as “the Guideline Development Group (GDG)
did not consider this topic as a health economic priority”. The
only independent evaluation conducted to inform the GDG’s
recommendations examined alternative strategies used for stag-
ing of the cancer before surgery.
For colorectal cancer, the recommendations for laparo-
scopic surgery in the current UK clinical guidelines (41)
were taken directly from NICE technology appraisal guidance
on “Laparoscopic surgery for colorectal cancer TA105” (42),
which used cost-effectiveness evidence reported in an article
included in the current review (23). Although this evidence sug-
gested laparoscopic surgery was dominated by open surgery, the
laparoscopic surgery was recommended over open surgery as
the NICE committee informed by TA105 were “persuaded there
were important differences” in length of stay and return to nor-
mal activities for laparoscopic surgery, and even though costs
were greater and there was little direct evidence of quality of life
benefits, “it was likely that such benefits exist . . . . . . . . . . and
these would be sufficient to make laparoscopic procedures cost-
effective”. For prostate cancer, the existing cost-effectiveness
evidence was considered to be limited as none included evi-
dence from a recently published RCT, hence, a de novo model
(included in this review) was constructed to incorporate these
data (see 28).
Authors of a recent report expressed concern with regard
to the future of academic surgery in the United Kingdom and
highlighted the need for additional research activities in can-
cer surgery and in particular multidisciplinary research (40).
Surgery is often associated with the greatest potential benefit
(cure/not cure) and potential harm (risk of morbidity/mortality)
when comparing modalities in the cancer treatment pathway
(40). It is, therefore, likely that new surgical devices and changes
in techniques and timing will be cost-effective and even poten-
tially cost-saving compared with pharmaceutical interventions.
However, such a proposition needs to be evidence-based and the
scarcity of economic evidence on surgical techniques suggests
that this is one area where the surgical community and policy-
decision makers could benefit from a wider multi-disciplinary
approach to research.
CONCLUSION
There is a dearth of recent robust evidence describing the
cost-effectiveness of surgical interventions in these indications.
Many of the recent publications did not satisfy essential require-
ments such as exploring the full uncertainty associated with the
evidence or using clinical evidence informed by a systematic
review and synthesis. Policy decisions for surgical techniques
in these indications do not appear to be informed by robust
economic evidence in all cases and due to the ratio of poten-
tial benefit and harm associated with cancer surgery there is an
urgent need to increase economic activities in this area.
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